JP2020529434A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529434A5
JP2020529434A5 JP2020505844A JP2020505844A JP2020529434A5 JP 2020529434 A5 JP2020529434 A5 JP 2020529434A5 JP 2020505844 A JP2020505844 A JP 2020505844A JP 2020505844 A JP2020505844 A JP 2020505844A JP 2020529434 A5 JP2020529434 A5 JP 2020529434A5
Authority
JP
Japan
Prior art keywords
inhibitors
dose
pharmaceutical composition
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020505844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529434A (ja
JP7417515B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/045195 external-priority patent/WO2019028367A1/en
Publication of JP2020529434A publication Critical patent/JP2020529434A/ja
Publication of JP2020529434A5 publication Critical patent/JP2020529434A5/ja
Priority to JP2023192683A priority Critical patent/JP7811933B2/ja
Application granted granted Critical
Publication of JP7417515B2 publication Critical patent/JP7417515B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020505844A 2017-08-04 2018-08-03 活動性好酸球性食道炎を治療する方法 Active JP7417515B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023192683A JP7811933B2 (ja) 2017-08-04 2023-11-13 活動性好酸球性食道炎を治療する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762541242P 2017-08-04 2017-08-04
US62/541,242 2017-08-04
US201762561593P 2017-09-21 2017-09-21
US62/561,593 2017-09-21
EP18305252 2018-03-08
EP18305252.1 2018-03-08
PCT/US2018/045195 WO2019028367A1 (en) 2017-08-04 2018-08-03 METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023192683A Division JP7811933B2 (ja) 2017-08-04 2023-11-13 活動性好酸球性食道炎を治療する方法

Publications (3)

Publication Number Publication Date
JP2020529434A JP2020529434A (ja) 2020-10-08
JP2020529434A5 true JP2020529434A5 (https=) 2021-09-02
JP7417515B2 JP7417515B2 (ja) 2024-01-18

Family

ID=63113646

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020505844A Active JP7417515B2 (ja) 2017-08-04 2018-08-03 活動性好酸球性食道炎を治療する方法
JP2023192683A Active JP7811933B2 (ja) 2017-08-04 2023-11-13 活動性好酸球性食道炎を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023192683A Active JP7811933B2 (ja) 2017-08-04 2023-11-13 活動性好酸球性食道炎を治療する方法

Country Status (9)

Country Link
EP (1) EP3661551A1 (https=)
JP (2) JP7417515B2 (https=)
KR (2) KR20240152980A (https=)
CN (1) CN111032084A (https=)
AU (2) AU2018311981B2 (https=)
CA (1) CA3071528A1 (https=)
IL (2) IL315556A (https=)
MA (1) MA49744A (https=)
MX (2) MX2020001305A (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023527775A (ja) * 2020-05-22 2023-06-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法
GB202102277D0 (en) * 2021-02-18 2021-04-07 Nordic Bioscience As Immunoassay for detecting Eosinophilic Esophagitis
EP4091615A1 (en) * 2021-05-20 2022-11-23 Dr. Falk Pharma Gmbh Orodispersible effervescent tablet comprising budesonide for use in the treatment of eosinophilic esophagitis
AU2023259287A1 (en) * 2022-04-29 2024-12-12 Akeso Biopharma, Inc Anti-human il-4ra antibody and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI634900B (zh) * 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
SG11201603127WA (en) * 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
BR112017019412A2 (pt) * 2015-03-11 2018-05-02 Glaxosmithkline Ip Dev Ltd proteínas ligadoras de tslp

Similar Documents

Publication Publication Date Title
JP2016528207A5 (https=)
HRP20200628T1 (hr) Metode za liječenje eozinofilnog ezofagitisa primjenom inhibitora il-4r
US11053309B2 (en) Methods for treating active eosinophilic esophagitis
Teitelbaum et al. Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate
JP2019531273A5 (https=)
JP7805549B2 (ja) 抗ｉｌ－１３抗体を使用する、ｉｌ－１３活性が有害である疾患の治療方法
JP2020529434A5 (https=)
Lehman et al. Eosinophilic esophagitis
JP2016521713A5 (https=)
JP2024016237A5 (https=)
JP7811933B2 (ja) 活動性好酸球性食道炎を治療する方法
JP2020502261A5 (https=)
JPWO2021237110A5 (https=)
KR20220103750A (ko) S1p1 수용체와 관련된 상태를 치료하는 방법
RU2022119098A (ru) Способы лечения активного эозинофильного эзофагита
Colice Emerging therapeutic options for asthma
Kuźmiński et al. Eosinophilic esophagitis. What diet? How to treat it? The point of view of a gastroenterologist working in a department of allergology
NZ779309A (en) Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
WO2025221247A1 (en) Treatment of eosinophilic esophagitis with anti-tslp antibody
NZ779309B2 (en) Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
Boulet Pathophysiology of asthma
Sánchez et al. New Therapies for Asthma: What Else Besides Steroids?
Kusama et al. Midazolam inhibits IgE production in mice via suppression of class switch recombination